Records EBITDA at Rs 372 crores
The board of Jubilant Life Sciences has approved the financial results for the quarter ended June 30, 2016. In Q1 FY17, the company’s consolidated revenue was at Rs 1,420 crores, the pharma revenue at Rs 752 crore, contributing 53 per cent to the overall mix, drug discovery solutions revenue at Rs 50 crore, contributing three per cent to the overall mix and international revenues at Rs 1,050 crore, contributing 74 per cent to the overall mix.
Earnings before interest, tax, depreciation and amortisation (EBITDA) was at Rs 372 crores, improving by 13 per cent Y-o-Y with EBITDA margins at 26.2 per cent, up from 22.7 per cent in Q1’16. The pharma segments contribution was about 70 per cent of the company’s EBITDA margins, at 34 per cent, up from 32.2 per cent in Q1’16.
The life science ingredients (EBITDA) margins was at 19 per cent, up from 17.2 per cent in Q1 FY16. Drug discovery solutions EBITDA margins was at 32.2 per cent, up from -3.5 per cent in Q1’16. Profit after tax was at Rs 162 crore, up 22 per cent Y-o-Y, with an EPS of Rs 10.15 in the quarter. The capital expenditure was at Rs 41 crores, net debt reduction at Rs 247 crore.
Shyam S Bhartia, Chairman and Hari S Bhartia, Co-Chairman and Managing Director, Jubilant Life Sciences said, “We have started the Year FY 2017 on a positive note delivering strong performance in pharmaceuticals segment which contributed about 70 per cent of the company’s operating profit. We are glad to state that our company has built a robust long-term sustainable business model with the growth engine of pharmaceuticals and drug discovery solutions segments. By creating focussed management teams for all the three segments of businesses, we are able to clearly define strategic initiatives with the right mix of capital allocation. We believe that the company will continue to deliver better performance going forward given the robust product pipeline in place.”
EP News Bureau – Mumbai
Comments are closed.